Prognostic and Therapeutic Applications of RKIP in Cancer

Edited by:   Benjamin Bonavida (Professor Department of Microbiology Immunology and Molecular Genetics David Geffen School of Medicine University of California USA), Stavroula Baritaki, PhD (Division of Surgical Oncology, School of Medicine, University of Crete, Heraklion, Crete, Greece)
Imprint:   Academic Press Inc
Country of Publication:   United States
Dimensions:   Height: 234mm,  Width: 191mm, 
Weight:   1.110kg
ISBN:   9780128196120
ISBN 10:   0128196122
Pages:   504
Publication Date:   05 February 2020
Audience:   Professional and scholarly ,  Undergraduate
Format:   Hardback
Publisher's Status:   Active

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005). Stavroula Baritaki’s, PhD, is currently Professor in Experimental Oncology at the University of Greece,. Her areas of expertise include the understanding of the molecular mechanisms involved in tumour cell therapeutic resistance and acquisition of a metastatic phenotype. Her studies have revealed novel gene products, including Raf-1 Kinase inhibitory protein (RKIP),. Followed by further studies on the epigenetic and post-translational regulation of RKIP in many cancer types, her overall findings have firstly suggested the RKIP downregulation in cancer cells as a putative gene signature of tumor chemo/immune-resistance and EMT with prognostic and therapeutic significance in an individualized basis. On this context, Dr. Baritaki has extended her research interests in identifying novel agents that through RKIP induction are able to inhibit EMT or improve either the host immunosurveillance and/or the efficacy of anti-tumor therapies, especially if they are combined with conventional immuno-stimulatory or chemotherapeutic regimens. Most of these agents are currently under clinical trials.